| 23rd week of 2016 patent applcation highlights part 10 |
| Patent application number | Title | Published |
|---|
| 20160158318 | METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE - The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands. | 2016-06-09 |
| 20160158319 | REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) - The present invention relates to mutants of Fibroblast Growth Factor (FGF), particularly FGF-20 and FGF-21, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compositions comprising the mutants and method for using the mutants. | 2016-06-09 |
| 20160158320 | DEVICE AND METHOD FOR THE DELIVERY OF DRUGS FOR THE TREATMENT OF POSTERIOR SEGMENT DISEASE - Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment. | 2016-06-09 |
| 20160158321 | TREATMENT OF PEDIATRIC GROWTH HORMONE DEFICIENCY WITH HUMAN GROWTH HORMONE ANALOGUES - The present invention concerns a pediatric growth hormone deficiency (PGHD) therapy for pediatric subjects. The therapy comprises administering to the pediatric patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein in therapeutically effective doses every week, every two weeks, semimonthly, every three weeks, or monthly. This therapy is not inferior compared to the height velocity achieved with daily injections of hGH not linked to XTEN over the same period. | 2016-06-09 |
| 20160158322 | NDP-MSH FOR TREATMENT OF INFLAMMATORY AND/OR NEURODEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM - The present invention is related to NDP-MSH or pharmaceutically acceptable salts thereof for therapeutic and/or prophylactic therapeutic treatment of inflammatory and/or neurodegenerative disorders of the CNS or multiple sclerosis. The present invention is further related to pharmaceutical compositions and a kit comprising NDP-MSH or pharmaceutically acceptable salts thereof. | 2016-06-09 |
| 20160158323 | Fibrinogen Preparations Enriched in Fibrinogen With An Extended Alpha Chain - The present invention relates to fibrinogen preparations enriched in α-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of α-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by α-extended fibrinogen are improved. In addition, plasmin-mediated degradation of α-extended fibrinogen is reduced as compared to plasma derived fibrinogen. | 2016-06-09 |
| 20160158324 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE - The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome. | 2016-06-09 |
| 20160158325 | METHOD OF TREATING FIBROPROLIFERATIVE DISORDERS INCLUDING DUPUYTREN'S DISEASE WITH ONE OR MORE SPECIFIC HUMAN MATRIX METALLOPROTEINASE AND A TNF ANTAGONIST - The subject invention also provides a method of treating a subject afflicted with a fibroproliferative disorder comprising periodically administering to the patient an amount of one or more human matrix metalloproteinase, wherein the one or more human matrix metalloproteinase are selected from human metalloproteinase-1 (MMP-1), human metalloproteinase-2 (MMP-2), human metalloproteinase-3 (MMP-3), human metalloproteinase-7 (MMP-7), human metalloproteinase-8 (MMP-8), human metalloproteinase-9 (MMP-9), human metalloproteinase-10 (MMP-10), human metalloproteinase-11 (MMP-11), metalloproteinase-12 (MMP-12), and human metalloproteinase-13 (MMP-13), and wherein the amount is effective to treat the subject. In an embodiment, the invention further comprises periodically administering to the subject an amount of TNF antagonist, wherein the amount of one or more the human matrix metalloproteinase and the amount of TNF antagonist when taken together are effective to treat the subject. | 2016-06-09 |
| 20160158326 | METHODS AND FEED SUPPLEMENTS FOR IMPROVING NUTRITION INTAKE OF MEAT-TYPE POULTRIES - The present invention provides methods of improving growth performance, improving the efficiency of feed utilization, and increasing feed digestibility of poultry receiving animal feed. Composition of the multi-component enzyme mixture designed to achieve the same are also provided. | 2016-06-09 |
| 20160158327 | GENETICALLY MODIFIED BABESIA PARASITES EXPRESSING PROTECTIVE TICK ANTIGENS AND USES THEREOF - The present invention relates to methods for stable transfection of | 2016-06-09 |
| 20160158328 | Method for allogeneic cell therapy - A method of manipulating allogeneic cells for use in allogeneic cell therapy providing a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism, or “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect The anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in a patient. | 2016-06-09 |
| 20160158329 | VACCINES COMPRISING LEISHMANIA POLYPEPTIDES FOR THE TREATMENT AND DIAGNOSIS OF LEISHMANIASIS - Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise polypeptides comprising one or more | 2016-06-09 |
| 20160158330 | METHODS OF PREPARATION AND COMPOSITION OF PEPTIDE CONSTRUCTS USEFUL FOR TREATMENT OF RHEUMATOID ARTHRITIS - The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of autoimmune diseases, specifically rheumatoid arthritis (RA) and compositions containing same, methods for producing same and methods for using same; wherein the peptide constructs have the formula | 2016-06-09 |
| 20160158331 | COMPOSITIONS AND METHODS FOR TREATMENT OF NON-HODGKINS LYMPHOMA - The present invention provides recombinant peptides comprising a B cell receptor (BCR) or a fragment thereof, nucleotide molecules encoding same, and vaccines and vectors comprising same; and methods of treating, inducing an immune response against, inducing a regression of, and suppressing a formation of a lymphoma, comprising administering same. The present invention also provides methods of inducing a humoral immune response in an animal against an antigen, comprising administering to the animal a fusion peptide comprising an LLO protein or fragment thereof fused to the antigen. | 2016-06-09 |
| 20160158332 | VACCINE COMPRISING AMA1 AND RON2 - Disclosed is a vaccine comprising an immunogenic composition comprising a complex of AMA1 and RON2 (or a fragment thereof), which elicits an immune response to a | 2016-06-09 |
| 20160158333 | METHODS FOR PRODUCING SALMONELLA O-ANTIGEN CAPSULES, COMPOSITIONS AND USES THEREOF - Methods of purifying O-Ag capsules from an | 2016-06-09 |
| 20160158334 | IMMUNOMODULATORY MINICELLS AND METHODS OF USE - The present disclosure is related to immunomodulatory bacterial minicells and methods of using the minicells. | 2016-06-09 |
| 20160158335 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective | 2016-06-09 |
| 20160158336 | Attenuated Mannheimia haemolytica Vaccines and Methods of Making and Use - The present invention provides attenuated | 2016-06-09 |
| 20160158337 | CHLAMYDIA ANTIGENS - The invention provides | 2016-06-09 |
| 20160158338 | METHODS OF STIMULATING IMMUNITY EMPLOYING DENGUE VIRAL ANTIGENS - Compositions that include at least a portion of at least one pathogen-associated molecular pattern and at least a portion of at least one member selected from the group consisting of a Den1 viral envelope protein, a Den2 viral envelope protein, a Den3 viral envelope protein and a Den4 viral envelope protein are employed in methods to stimulate a protective immune response in a subject. | 2016-06-09 |
| 20160158339 | METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS - The invention relates to a method for inactivating viruses, characterized in that an immunogenic composition or vaccine comprising at least one virus is irradiated with electron beams, said immunogenic composition or vaccine comprising at least one virus (i) being liquid, in particular being a suspension and (ii) comprising at least one viral immunogen, wherein the antigen structure is preferably substantially retained. | 2016-06-09 |
| 20160158340 | INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX PROTEINS - An immunological composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in call culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g., a matrix M1 fragment with a molecular weight of less than 20 kDa. The composition may be a subunit vaccine comprising purified surface glycoproteins. | 2016-06-09 |
| 20160158341 | PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS - A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer. | 2016-06-09 |
| 20160158342 | VACCINES FOR DISEASES CAUSED BY VIRUSES OF THE FAMILY OF REOVIRIDAE - The invention relates to methods for producing a propagation-competent strain of a mutant Reoviridae virus, and to a propagation-competent strain of a mutant Reoviridae virus that is obtainable by a method of the invention. The invention further relates to a propagation-competent strain of a mutant Reoviridae virus, comprising a deletion of a genetic region that is relevant for propagation of the virus, and to a vaccine, comprising a propagation-competent strain of a mutant Reoviridae virus. | 2016-06-09 |
| 20160158343 | RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORS - Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided. | 2016-06-09 |
| 20160158344 | Methods And Compositions of Protein Antigens For The Diagnosis And Treatment of Herpes Simplex Viruses Type 1 And 2 - Contemplated compositions, devices, and methods are drawn to various antigens from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter. | 2016-06-09 |
| 20160158345 | PROCESS FOR PREPARING PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATES - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 2016-06-09 |
| 20160158346 | FUCOSYLLACTOSE AS BREAST MILK IDENTICAL NON-DIGESTIBLE OLIGOSACCHARIDE WITH NEW FUNCTIONAL BENEFIT - The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants. | 2016-06-09 |
| 20160158347 | Acceleration of Vector Virus Induced Immune Response in Avians - The addition of an oligodeoxynucleotide that is an avian TLR21 agonist, to an avian Herpesvirus vector vaccine, provides an acceleration of the immune response against the antigen that is expressed and delivered by the Herpesvirus vector. | 2016-06-09 |
| 20160158348 | Adjuvant Combinations of NKT Activator, CD40 Agent, CD40 Agonist, and Optional Antigen, the Use Through Inducing Synergistic Cellular Immunity - Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided. | 2016-06-09 |
| 20160158349 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS - The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. | 2016-06-09 |
| 20160158350 | ADJUVANT COMPOSITIONS AND METHODS OF USE - This disclosure provides adjuvant compositions that are capable of modulating the immune response in a subject. These adjuvant compositions may also be used enhance the immunogenicity of antigens. Also provided are methods of making the adjuvant compositions as well as methods of using the adjuvant compositions. | 2016-06-09 |
| 20160158351 | PHARMACEUTICAL COMPOSITIONS COMPRISING ATTENUATED PLASMODIUM SPOROZOITES AND GLYCOLIPID ADJUVANTS - Disclosed herein are pharmaceutical compositions comprising | 2016-06-09 |
| 20160158352 | APOPTOTIC CELL-MEDIATED INDUCTION OF ANTIGEN SPECIFIC REGULATORY T-CELLS FOR THE THERAPY OF AUTOIMMUNE DISEASES IN ANIMALS AND HUMANS - The invention provides methods of tolerizing or treating a subject suffering from an autoimmune or autoinflammatory disease or disorder to an antigen associated with the autoimmune disease or disorder. The invention also features kits for carrying out the methods of the invention. | 2016-06-09 |
| 20160158353 | Compositions and Methods for the Treatment of Biofilm Infections - Compositions and methods for preventing, ameliorating or treating biofilm infections are provided, including biofilms comprising at least one Pseudomonad or | 2016-06-09 |
| 20160158354 | Messenger RNA Therapy for Treatment of Articular Disease - The present invention provides, among other things, a method of intra-articular delivery of messenger RNA (mRNA), comprising administering into a joint of a subject in need of delivery a composition comprising an mRNA encoding a protein, such that the administering of the composition results in expression of the protein encoded by the mRNA in the joint. | 2016-06-09 |
| 20160158355 | IMMUNOPOTENTIATIVE COMPOSITION - Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. | 2016-06-09 |
| 20160158356 | IMMUNOPOTENTIATIVE COMPOSITION - Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. | 2016-06-09 |
| 20160158357 | METHODS OF TREATING ANAEMIA - The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method. | 2016-06-09 |
| 20160158358 | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) - This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast). | 2016-06-09 |
| 20160158359 | METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY - Provided are methods for multiple administrations of cells for adoptive cell therapy, and for administering cells to subjects having received prior administrations, and compositions and articles of manufacture for use in the methods. The cells generally express recombinant molecules such as recombinant receptors, e.g., chimeric antigen receptors (CARs) and/or other transgenic receptors. The methods can involve administering cells expressing a first or prior receptor(s) and cells expressing a second or subsequent receptor(s), the second or subsequent receptor(s) being distinct from the first, and which generally do not express the first receptor, and/or administering the cells expressing the second receptor to a subject having received the first administration. The methods can provide various advantages, such as improved efficacy in the context an immune response in the subject against the first or prior receptor and/or in the context of antigen loss, downregulation, or modification, following a first or prior administration. | 2016-06-09 |
| 20160158360 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS ANTAGONISTS AND HPK1 ANTAGONISTS - Compositions and methods for enhancing an immune response and treating cancer are provided. Compositions comprise PD-1 axis antagonists and HPK1 antagonists. PD-1 axis antagonists include PD-1 antagonists, PD-L1 antagonists, and PD-L2 antagonists. PD-1 axis antagonists can inhibit the binding of PD-L1 and/or PD-L2 to PD-1. HPK1 antagonists include compounds that inhibit the serine/threonine kinase activity of HPK1. Methods for enhancing an immune response or treating cancer comprise administering a PD-1 axis antagonist and a HPK1 antagonist, sequentially or simultaneously, to a subject in need thereof. | 2016-06-09 |
| 20160158361 | Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 2016-06-09 |
| 20160158362 | Liquid Bendamustine Formulation - The present invention provides stable bendamustine-containing pharmaceutical compositions suitable for long term storage. The compositions include bendamustine, a pharmaceutically acceptable salt, and/or a hydrate form thereof, a solvent mixture of N,N-dimethylacetamide and glycerin, and an antioxidant. The bendamustine-containing compositions have less than about 2% of total impurities after two month storage at 25° C./60% RH. The pharmaceutical compositions may be used for treating neoplastic diseases. | 2016-06-09 |
| 20160158363 | MULTI-TAILED LIPIDS AND USES THEREOF - The present invention provides multi-tailed lipid compounds, and salts and stereoisomers thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an siRNA, mRNA, plasmid DNA, small molecule, protein, peptide). The present invention also provides methods, and kits using the compositions for delivering an agent to a subject (e.g., to the liver, spleen, or lung of the subject) or cell and for treating and/or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, immunological diseases, gastrointestinal diseases (e.g., liver diseases), respiratory diseases (e.g., lung diseases), painful conditions, psychiatric disorders, metabolic disorders, and spleen diseases. | 2016-06-09 |
| 20160158364 | Menthol-based Nanoparticles for Drug Delivery - The subject invention pertains to formulations comprising poly(menthyl acrylate) nanoparticles comprising at least one active ingredient contained in a plurality of hydrophobic carriers and dispersed in an aqueous medium. The subject invention further pertains to methods of polymerization of drug loaded nanoparticles made up of methyl acrylate monomers in an aqueous emulsion. | 2016-06-09 |
| 20160158365 | METHODS AND COMPOSITIONS FOR TREATING RECURRENT CANCER - The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein. | 2016-06-09 |
| 20160158366 | CLATHRIN THERAPEUTIC FOR AUTOIMMUNE DISEASES - The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating an autoimmune disease, condition, or disorder in vivo or in vitro. | 2016-06-09 |
| 20160158367 | CLATHRIN THERAPEUTIC FOR NEUROLOGICAL DISEASES - The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating a neurological disease, condition, or disorder in vivo or in vitro. | 2016-06-09 |
| 20160158368 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HISTIOCYTOSIS - The present application provides methods of treating CD163 | 2016-06-09 |
| 20160158369 | PHARMACEUTICAL COMPOSITION FOR RESPIRATORY ADMINISTRATION - The present invention provides a pharmaceutical composition for respiratory administration containing a polysaccharide derivative having a group derived from a polysaccharide and a group derived from a physiologically active substance that is covalently bonded to the group derived from a polysaccharide. | 2016-06-09 |
| 20160158370 | WOUND HEALING USING TOPICAL SYSTEMS AND METHODS - The present invention generally relates to compositions and methods for topical or transdermal delivery and treatment of wounds and/or promoting wound healing. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., wounded skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-06-09 |
| 20160158371 | METHODS AND SYSTEMS FOR TREATING OR PREVENTING CANCER - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-06-09 |
| 20160158372 | CARDIOVASCULAR DISEASE TREATMENT AND PREVENTION - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-06-09 |
| 20160158373 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES - A particulate, barrier coated drug-anion exchange resin complex comprising a core composed of an acidic drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The barrier coating contains a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described. | 2016-06-09 |
| 20160158374 | CELL-PENETRATING PEPTIDE AND CONJUGATE COMPRISING SAME - The present invention relates to a cell-penetrating peptide derived from telomerase, a conjugate of the cell-penetrating peptide with an anticancer agent, and a composition comprising the conjugate. An effective means for transferring a cancer-specific anticancer agent can be provided by using the cell-penetrating peptide according to the present invention. More particularly, by preparing the conjugate of the present invention wherein the cell-penetrating peptide and the anticancer agent are combined, the application concentration of a conventional anticancer agent can be reduced and cancer specificity can be provided, and thus an effect of reducing side effects during the treatment process can be obtained. | 2016-06-09 |
| 20160158375 | DIPEPTIDE LINKED MEDICINAL AGENTS - A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipeptide element provides a means of linking various compounds to known medicinal agents wherein the compounds are subsequently released from the medicinal agent after a predetermined time of exposure to physiological conditions. For example, the dipeptide can be linked to an active site of a drug to form a prodrug and/or the dipeptide may comprise a depot polymer to sequester an injectable composition comprising the complex at the point of administration. | 2016-06-09 |
| 20160158376 | PHARMACEUTICAL, WATER-SOLUBLE AND ANTIFUNGAL MACROMOLECULAR COMPOUND - The present invention relates to a medicinal water-soluble antifungal macromolecular compound used for treating infectious diseases, especially, relates to a poly-conjugate which includes an active drug substance and a macro-molecular polymer which are combined with each other through chemical bonds. The active drug substance is a polyene macrolide compound such as amphotericin B. Also provided are a method of preparing the poly-conjugate, a method for increasing solubility of the active drug substance and a method for treating fungal infection, which is any disease related to fungus, such as sepsis, endocarditis, meningitis (caused by | 2016-06-09 |
| 20160158377 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same - Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway. | 2016-06-09 |
| 20160158378 | CONJUGATE OF BIOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND IMMUNOGLOBULIN FC FRAGMENT WITH REDUCED RECEPTOR-MEDIATED CLEARANCE, AND THE METHOD FOR PREPARING THE SAME - Provided is a long-acting pharmaceutical composition containing a conjugate comprising a physiologically active polypeptide linked to an immunoglobulin Fc fragment, wherein the composition contains a monomeric conjugate comprising one molecule of the physiologically active polypeptide linked to a single immunoglobulin Fc fragment, and optionally contains a multimeric conjugate comprising two or more molecules of the same physiologically active polypeptide linked to a single immunoglobulin Fc fragment, provided that the molar ratio of the monomeric conjugate to the multimeric conjugate in the composition is at least 19; a physiologically active polypeptide monomer-immunoglobulin Fc fragment conjugate that comprises a physiologically active polypeptide monomer linked via a non-peptidyl linker to an immunoglobulin Fc fragment, wherein the physiologically active polypeptide is linked via the non-peptidyl linker to the immunoglobulin Fc fragment in a monomeric form. | 2016-06-09 |
| 20160158379 | KITS CONTAINING DLL3 ANTIBODY DRUG CONJUGATES - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 2016-06-09 |
| 20160158380 | Anti-Claudin 1 Antibodies for Use in the Treatment of Colorectal Cancer - The present invention relates to anti-claudin 1 antibodies for use in the treatment of colorectal cancer. In particular, the present invention relates to a method of treating a colorectal cancer in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an anti-claudin 1 (CLDN1) antibody. | 2016-06-09 |
| 20160158381 | NOVEL NANOLIPOSOMES AND THEIR USE FOR THE TREATMENT OF AMYLOID PROTEIN DISEASES - Generally provided herein are methods, compounds, and compositions described useful for the treatment of light chain amyloidosis and other amyloid protein diseases. | 2016-06-09 |
| 20160158382 | AGENT FOR THE TREATMENT AND PREVENTION OF SLEEP DISORDERS - The invention relates to the fields of pharmaceutics and medicine and describes an agent for the treatment and prevention of sleep disorders, wherein a conjugate of glycine immobilized on detonation nanodiamond particles 2-10 nm in size comprises 21±3 wt. % glycine. Said preparation improves the outcome of pharmacotherapy and prevention of sleep disorders, in particular, insomnia, and leads to the creation of a greater number of effective and safe sedative-hypnotic medications. | 2016-06-09 |
| 20160158383 | METHOD AND DEVICE FOR MANUFACTURING POLYMER PARTICLES CONTAINING A THERAPEUTIC MATERIAL - Methods and devices for manufacturing polymer particles containing a therapeutic material and polymer conjugate particles comprising (a) introducing a first stream comprising a first solvent into a channel, wherein the channel has a first region adapted for flowing one or more streams introduced into the channel and a second region for mixing the contents of the one or more streams; (b) introducing a second stream comprising polymer conjugate in a second solvent into the channel to provide first and second streams flowing in the channel; (c) flowing the one or more first streams and the one or more second streams from the first region of the channel into the second region of the channel; (d) mixing of the contents of the one or more first streams and the one or more second streams flowing in the second region of the channel to provide a third stream comprising polymer conjugate nanoparticles. | 2016-06-09 |
| 20160158384 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS - SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length. | 2016-06-09 |
| 20160158385 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2016-06-09 |
| 20160158386 | MODEL OF COLORECTAL CANCER - A model of colorectal cancer that recapitulates the pathogenesis of the human disease is disclosed. Also provided are methods of generating the model of colorectal cancer, as well as methods of using the model to screen for compounds that inhibit tumorigenesis. | 2016-06-09 |
| 20160158387 | COATED MAGNETIC NANOPARTICLES - Disclosed herein are polymer-coated iron oxide magnetic nanoparticles and methods of their manufacture and use. The nanoparticles are coated with a copolymer of poly(maleic anhydride alt-H2C═CH—R1)-polyethylene glycol (PMAR-PEG), wherein R1 is a hydrophobic moiety. The molecular weights of the PMAR and PEG portions of the copolymer, as well as the core diameter of the nanoparticles are selected in order to produce optimal performance for specific applications. Representative applications of the nanoparticles include magnetic particle imaging, magnetic sentinel lymph node biopsy, and magnetic fluid hyperthermia. The disclosed nanoparticles are tools for these methods that provide previously unachieved levels of stability (e.g., via reduced agglomeration) and customizability (e.g., tuned blood circulation half-life in vivo). | 2016-06-09 |
| 20160158388 | TARGETED, METAL-CATALYZED FLUORINATION OF COMPLEX COMPOUNDS WITH FLUORIDE ION VIA DECARBOXYLATION - Methods of preparing fluorinated compounds by carboxylative fluorination using fluoride are contained herein. Fluorinated compounds are provided. Methods of using fluorinated compounds are contained herein. | 2016-06-09 |
| 20160158389 | IMAGING TUMOR GLYCOLYSIS BY NON-INVASIVE MEASUREMENT OF PYRUVATE KINASE M2 - A novel pyruvate kinase M2 (PKM2)-specific activator, [ | 2016-06-09 |
| 20160158390 | Methods for Tumor Diagnosis and Therapy - The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule. | 2016-06-09 |
| 20160158391 | IMAGE GUIDED BORONATED GLUCOSE NEUTRON CAPTURE THERAPY - Disclosed herein are methods, processes, devices, and compositions for the treatment of target cells and/or tissues, the treatment comprising identifying the target cell with positron emission tomography and then directing a epithermal neutron toward the identified target cell. In various aspects, the target cells and/or tissues take up and metabolize boronated glucose and radioactive fluorinated glucose molecules. | 2016-06-09 |
| 20160158392 | Entrapment of Radionuclides in Nanoparticle Compositions - The present invention is directed to the technical field of imaging compositions useful for diagnosing cancer and other diseases in a subject. In particular, the invention relates to a class of diagnostic compounds comprising a novel liposome composition with encapsulated metal entities such as radionuclides, for example | 2016-06-09 |
| 20160158393 | Method for Improving Health Outcomes - Method of using an antiseptic and pH modulating solution provides improved health outcomes in part by decolonizing surfaces, animate and inanimate, and improving tissue function and stress response, particularly the barrier properties and antimicrobial properties of tissues, especially skin and muscles, whether damaged or intact and at risk of damage. The method includes initial application followed by continued topical application on a periodic basis until the damaged area is restored or the risk of injury has passed, followed by continued maintenance application for a period of time thereafter. The method of using the solution is believed to restore and improve the functioning of tissues that naturally interrupt pathogenic mechanisms of disease in addition to providing antimicrobial support. The method can be adapted to improve a plurality of health or consumer care outcomes, from preventing or substantially reducing rates of hospital acquired infections to improving muscle performance and recovery, among others. | 2016-06-09 |
| 20160158394 | SYSTEMS AND CONTAINERS FOR STERILZING A FLUID - A system for sterilizing a fluid includes a sterilization container bounding a fluid flow path that can be coupled with a fluid source. The sterilization container is comprised of one or more polymeric walls. A beam generator is configured to direct a beam of electromagnetic radiation through at least a portion of the fluid flow path of the sterilization container, the beam of electromagnetic radiation being sufficient to sterilize a fluid within the fluid flow path. | 2016-06-09 |
| 20160158395 | UVC Sterilization Box Electronics Devices - A sterilization method and apparatus for cleaning multiple devices of different sizes on all surfaces at one time. This apparatus allows for the cleaning of electronic devices which are corded and cordless/wireless without allowing ozone which is generated from the UV lights to escape from the product or allowing humans eyes to be effected by direct exposure to the UV light generated by the apparatus. This apparatus enables devices to be charged while they are being sterilized. This invention outlines a very simple method for replacement of fragile cold cathode lamps using a wire harness and metalized enclosure | 2016-06-09 |
| 20160158396 | Self-Cleaning Surfaces - New forms of self-sterilizing and antiseptic surfaces are provided. In some embodiments, a handled surface or GUI comprises internal hardware performing a heavy rinse of the handled surface triggered by an end-of-use function. In other embodiments, pressure on a handled surface instead causes the surface to uniformly exude water and other antiseptic compositions from a refillable source. | 2016-06-09 |
| 20160158397 | Device for Evaporating a Volatile Material - An assembly for evaporating a volatile material is described, the assembly comprising a device and a refill which are detachable from one another: wherein the device comprises a magnetic induction coil configured to operate with an alternating current passed therethrough at a frequency of between substantially 20 KHz to substantially 500 KHz and one or more volatile fluid emanation channels containing at least one piece of heat-conducting, non-magnetic metal foil and/or deposited heat-conducting, non-magnetic metal; and wherein the refill comprises at least one magnetic susceptor having a coercivity of substantially 50 ampere/metre (H | 2016-06-09 |
| 20160158398 | Fragrance Dispensing Apparatus - An apparatus for dispersing an aromatic fragrance includes an oscillating fan, a stand, a base, a fragrance dispenser, and a fragrance container. The fragrance dispensing apparatus is used to evenly and effectively disperse a fragrance throughout a room or household. | 2016-06-09 |
| 20160158399 | USING VORTEX RINGS TO DELIVER GASES AT A DISTANCE - A system for delivering vortex rings to an intended target includes a vortex ring generator, one or more component storage containers, and a component additive mechanism. The vortex ring generator is configured to deliver and air vortex rings. The component additive mechanism is configured to remove a component from at least one of the one or more component storage containers, generate a gas from the component, and to add the gas to a vortex ring after the vortex ring is generated by the vortex ring generator. | 2016-06-09 |
| 20160158400 | ULTRAVIOLET STERILIZATION AND DISINFECTION DEVICE AND CONFIGURATION METHOD THEREOF - Provided herein is an ultraviolet sterilization and disinfection apparatus. One or multiple low-pressure ultraviolet lamps are arranged within the ultraviolet sterilization and disinfection apparatus. A configuration method therefor is such that the inner diameters of the low-pressure ultraviolet lamps are Φ30-36 mm and the tube current density is: 0.250-0.800 A/cm2; alternatively the inner diameters are Φ26-30 mm and the tube current density is: 0.280-0.850 A/cm2; alternatively, the inner diameters are Φ20-26 mm and the tube current density is: 0.300-1.100 A/cm2; alternatively, the inner diameters are Φ15-20 mm and the tube current density is: 0.340-1.350 A/cm2. The method allows the ultraviolet dosage of the ultraviolet sterilization and disinfection apparatus to be increased, thus increasing efficiency in sterilization and disinfection. | 2016-06-09 |
| 20160158401 | SANITARY ARTICLE AND METHOD FOR MAKING THE SAME - A sanitary article includes an absorbent pad including an upper sheet layer, a lower sheet layer, and a pulp-and-SAP powder layer combination. The powder layer combination is constituted by alternate layers of pulverized pulp and superabsorbent polymer (SAP) powder. A method for making the sanitary article is also disclosed. | 2016-06-09 |
| 20160158402 | COMPOSITIONS AND DEVICES OF POLY-4-HYDROXYBUTYRATE - Compositions of P4HB with high purity have been developed. The compositions are prepared by washing P4HB biomass prior to solvent extraction, and precipitating P4HB from solution. The same solvent is preferably used to wash the P4HB biomass, and as a non-solvent to precipitate the polymer from a P4HB solvent solution. The highly pure P4HB compositions are suitable for preparing implants. The implants may be used for the repair of soft and hard tissues. | 2016-06-09 |
| 20160158403 | A WOUND DRESSING - The present invention relates to an impregnated wound dressing having an outer membrane overlay layer and to a method of production thereof. In particular the dressing comprises a core layer that has been impregnated with a wound healing agent, such as honey, and an outer membrane overlay layer. | 2016-06-09 |
| 20160158404 | ARTICLES WITH ODOR-CONTROLLING COMPOSITION - Articles are treated with a reduced amount of a halo active aromatic sulfonamide compound of Formula (I): | 2016-06-09 |
| 20160158405 | LIPOSOMAL DRUG DELIVERY SYSTEM FOR BONE CEMENTS - The invention relates to a novel antibiotic delivery vehicle for impregnating bone cement wherein said vehicle is an antibiotic encapsulated liposome having a block co-polymer on its surface; a method for the manufacture of a bone cement impregnated with antibiotic or a mixture of antibiotics using said vehicle; and also a novel bone cement made therewith and/or thereby. | 2016-06-09 |
| 20160158406 | SELF-ASSEMBLING BIOMIMETIC HYDROGELS HAVING BIOADHESIVE PROPERTIES - The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal. The polymeric component is able to form covalent bonds with amine moieties in the aminated component, in one or more tissues in the body of the mammal, or both. Upon injection of a liquid suspension of these components into the body of the mammal, the thermally-desolubilizable polymer condenses, entrapping the polymeric component. The polymeric component binds covalently with a tissue in the body, and the aminated component end-caps the remaining reactive moieties of the polymeric component, forming a matrix at the site of injection. The disclosure also relates to uses of such compositions for forming a matrix on or within the body of a mammal. The compositions have a variety of uses, such as bioadhesives, as sealants for ruptured tissues, as drug or imaging agent depots, or as mechanical cushions. | 2016-06-09 |
| 20160158407 | Dry haemostatic composition - The present invention relates to a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form. The invention further relates to methods of preparing said dry composition, a paste made from said dry composition and use of said paste for medical and surgical purposes. | 2016-06-09 |
| 20160158408 | IRRIGATION RESISTANT COMPOSITIONS FOR REGENERATION OF HARD TISSUES AND METHODS OF USING THE SAME - An irrigation resistant bone repair composition including a biocompatible or bioactive bone repair material comprising borate, and poly(glycerol sebacate), wherein the composition, upon implantation into a surgical site, maintains position and does not displace upon irrigation of the surgical site, is described. Also, methods for treating a bone having a bone gap or a bone defect with the composition as well as kits that include the composition, are provided. | 2016-06-09 |
| 20160158409 | CALCIUM PHOSPHATE-BASED ADHESIVE FORMULATION FOR BONE FILLING - Calcium phosphate-based formulation for bone filling, comprising at least one adjuvant giving adhesion properties, wherein the at least one adjuvant is selected from the saccharide head surfactant group. The bone cement is characterized by adhesive properties particularly advantageous facilitating the setting of the cement and offering a better containment of the bone-cement or bone-cement-prosthesis interface. | 2016-06-09 |
| 20160158410 | POLYSACCHARIDE HYDROGELS FOR INJECTION WITH TUNABLE PROPERTIES - Injectable hydrogels comprising polysaccharides based on disaccharides the backbones of which form an α-helix structure and in which in at least 10% of the disaccharide units the primary hydroxyl groups are oxidized. | 2016-06-09 |
| 20160158411 | PROTEIN BIOMATERIALS AND BIOCOACERVATES AND METHODS OF MAKING AND USING THEREOF - The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g. stents, valves . . . ), vessels, tubular grafts, vascular grafts, wound healing devices including protein suture biomaterials and biomeshes, dental plugs and implants, skin/bone/tissue grafts, tissue fillers, protein biomaterial adhesion prevention barriers, cell scaffolding and other biocompatible biocoacervate or biomaterial devices. | 2016-06-09 |
| 20160158412 | ARTICLES COMPRISING LARGE-SURFACE-AREA BIO-COMPATIBLE MATERIALS AND METHODS FOR MAKING AND USING THEM - The present invention provides articles of manufacture comprising biocompatible nanostructures comprising significantly increased surface area for, e.g., organ, tissue and/or cell growth, e.g., for bone, tooth, kidney or liver growth, and uses thereof, e.g., for in vitro testing of drugs, chemicals or toxins, or as in vivo implants, including their use in making and using artificial tissues and organs, and related, diagnostic, screening, research and development and therapeutic uses, e.g., as drug delivery devices. The present invention provides biocompatible nanostructures with significantly increased surface area, such as with nanotube and nanopore array on the surface of metallic, ceramic, or polymer materials for enhanced cell and bone growth, for in vitro and in vivo testing, cleansing reaction, implants and therapeutics. The present invention provides optically transparent or translucent cell-culturing substrates. The present invention provides biocompatible and cell-growth-enhancing culture substrates comprising elastically compliant protruding nanostructure substrates coated with Ti, TiO | 2016-06-09 |
| 20160158413 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH - The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect. | 2016-06-09 |
| 20160158414 | Anisotropic Constructs and Methods for Forming and Using Same for Treating Damaged Biological Tissue - Anisotropic constructs having a base member with a defined surface that includes a plurality of substantially parallel equidistant linear channels that are configured to modulate the polarity and proliferation of cells through spatial and biomechanical cues. The constructs are also capable of administering a biologically active agent and/or a pharmacological composition to tissue. | 2016-06-09 |
| 20160158415 | METHOD FOR DETOXIFYING A BIOLOGICAL TISSUE - Biological tissues may be prepared for use in biological prostheses. The biological tissue may be fixated with glutaraldehyde and may be subjected to successive treatment of the tissue with a solution containing taurine to neutralize excess aldehyde groups that remain free after fixation. | 2016-06-09 |
| 20160158416 | SCAFFOLD FOR HARD TISSUE REGENERATION CONTAINING ACTIVE INGREDIENT FOR TREATING OSTEOPOROSIS AND PREPARING METHOD THEREOF - A scaffold for hard tissue regeneration comprising an active ingredient for treating osteoporosis and a preparation method thereof. The scaffold for hard tissue regeneration is prepared by the steps of mixing a polyphenol-based natural substance containing Quercetein or Genistein involved in the activation of osteoblasts and osteoclasts and the biofunctional analogue thereof with a ceramic scaffold material and molding the mixture at room temperature into a three-dimensional scaffold. The biofunctional material included in the scaffold above may be sustain-released slowly over the long period of time so that the osteoblast activity is directly improved and at the same time the osteoclast activity is suppressed in the course of bone regeneration, to have the effect of improving bone regeneration. | 2016-06-09 |
| 20160158417 | DYNAMIC POROUS COATING FOR ORTHOPEDIC IMPLANT - A dynamic porous coating for an orthopedic implant, wherein the dynamic porous coating is adapted to apply an expansive force against adjacent bone so as to fill gaps between the dynamic porous coating and adjacent bone and to create an interference fit between the orthopedic implant and the adjacent bone. | 2016-06-09 |
